ArticleFrontiers in cell and developmental biology2026
Cell death mechanisms, DAMP release, and therapeutic targeting in sepsis-associated postoperative pneumonia.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis complicating postoperative pneumonia activates multiple programmed cell death pathways-pyroptosis, necroptosis, and ferroptosis-which release DAMPs that amplify systemic inflammation and worsen outcomes. This study aimed to characterize clinical correlates of these pathways, identify biomarkers predictive of ARDS and mortality, and evaluate relevant therapeutic strategies. Methods: A single-center retrospective cohort of surgical patients over 12 years was analyzed. Patients developing postoperative pneumonia were stratified by sepsis and ARDS status. Systemic biomarkers, CT imaging, and survival outcomes were assessed using Cox regression, ROC analysis, and Kaplan-Meier modeling. Pathway-specific molecular assays were unavailable; all mechanistic interpretations are therefore hypothesis-generating. Results: Inflammatory biomarkers escalated progressively across the pneumonia-sepsis-ARDS continuum. Procalcitonin and NLR demonstrated utility in identifying high-risk patients before sepsis onset. CT-quantified bilateral ground-glass opacities predicted ARDS development, though ARDS-specific estimates should be treated as exploratory given the small subgroup size. Mortality rose substantially at each stage of clinical severity, with sepsis, ARDS, CT severity score, and bilateral pulmonary involvement each identified as independent mortality predictors. Conclusion: Programmed cell death pathways provide a conceptually consistent framework for the observed clinical continuum, but require prospective molecular validation. Biomarker panels and CT-based stratification support early risk identification and may improve postoperative surveillance. Investigational agents targeting key cell death mediators remain hypothesis-driven and are not yet clinically actionable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.